Nautilus Biotechnology, Inc.

Nautilus Biotechnology, Inc. (Nasdaq: NAUT) became a publicly traded company in June 2021 through its business combination with Arya Sciences Acquisition Corp III, a SPAC sponsored by Perceptive Advisors that completed its initial public offering in 2020. The company operates in the life sciences and biotechnology sector, focused on developing single-molecule protein sequencing technology intended to enable proteome-scale analysis for research and clinical applications. Nautilus filed an 8-K with the Securities and Exchange Commission on April 28, 2026, continuing its periodic disclosure obligations as a public company following the completion of its de-SPAC transaction. For comprehensive filing history, sponsor details, and real-time data on NAUT and thousands of other SPAC transactions, sign up for full access at SpacDesk.